The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the agency, stoking worries that the plan may run afoul of legal, ethical and scientific standards long used to vet the safety and effectiveness of new medicines.
Legal questions swirl around FDA's new expedited drug program, including who should sign off
By News Desk
News Desk
News Desk is the dedicated editorial force behind News On Click. Comprised of experienced journalists, writers, and editors, our team is united by a shared passion for delivering high-quality, credible news to a global audience.
Add A Comment